Valuation Sanofi Borsa Italiana

Stocks

End-of-day quote Borsa Italiana Other stock markets 2026-07-10			5-day change	1st Jan Change
76.09 ^EUR	-0.35%		+0.40%	-8.37%

07-10	Sanofi Receives Fda Approval for Subcutaneous Sarclisa Escena Administered Via On-Body Injector	CI
07-10	Sanofi Wins US FDA Approval for Subcutaneous Sarclisa Escena in Multiple Myeloma	MT

Data adjusted to current consolidation scope

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Market Cap ¹	111,194	112,665	112,549	116,968	100,655	91,493	-	-
Change	-	1.32%	-0.1%	3.93%	-13.95%	-9.1%	-	-
Enterprise Value (EV) ¹	121,177	119,102	120,342	125,740	111,663	101,124	97,012	93,612
Change	-	-1.71%	1.04%	4.49%	-11.2%	-9.44%	-4.07%	-3.51%
P/E	17.8x	16.7x	20.8x	20.4x	12.9x	11.5x	10.6x	8.97x
PBR	1.62x	1.5x	1.52x	1.51x	1.41x	1.22x	1.16x	1.1x
PEG	-	2.07x	-1.1x	3.14x	0.3x	3.25x	1.19x	0.5x
Capitalization / Revenue	2.94x	2.62x	2.61x	2.85x	2.31x	1.95x	1.83x	1.74x
EV / Revenue	3.21x	2.77x	2.79x	3.06x	2.56x	2.15x	1.94x	1.78x
EV / EBITDA	9.95x	8.14x	8.44x	9.76x	8.22x	6.91x	6.22x	5.48x
EV / EBIT	11.3x	9.13x	9.5x	11.1x	9.19x	7.87x	7.07x	6.25x
EV / FCF	15x	14x	14.2x	21.1x	13.8x	11.8x	10.7x	9.17x
FCF Yield	6.68%	7.12%	7.04%	4.74%	7.24%	8.49%	9.39%	10.9%
Dividend per Share ²	3.33	3.56	3.76	3.92	4.12	4.254	4.506	4.831
Rate of return	3.76%	3.96%	4.19%	4.18%	4.98%	5.58%	5.91%	6.34%
EPS ²	4.97	5.37	4.31	4.59	6.4	6.626	7.214	8.497
Distribution rate	67%	66.3%	87.2%	85.4%	64.4%	64.2%	62.5%	56.9%
Net sales ¹	37,761	42,997	43,070	41,081	43,626	46,952	50,037	52,697
EBITDA ¹	12,183	14,627	14,259	12,889	13,583	14,630	15,608	17,090
EBIT ¹	10,714	13,040	12,670	11,343	12,149	12,857	13,713	14,976
Net income ¹	6,223	6,720	5,400	5,744	7,813	7,990	8,903	10,549
Net Debt ¹	9,983	6,437	7,793	8,772	11,008	9,631	5,519	2,119
Reference price ²	88.58	89.84	89.76	93.74	82.72	76.23	76.23	76.23
Nbr of stocks (in thousands)	1,255,293	1,254,060	1,253,891	1,247,793	1,216,810	1,200,220	-	-
Announcement Date	2/4/22	2/3/23	2/1/24	1/30/25	1/29/26	-	-	-

¹EUR in Million²EUR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
ELI LILLY AND COMPANY	34.92x	12.63x	25.81x	0.57%	1,060B
JOHNSON & JOHNSON	27.42x	6.3x	17.1x	2.08%	619B
ABBVIE INC.	30.1x	7.34x	15.02x	2.76%	438B
ROCHE HOLDING AG	17.98x	4.45x	11.01x	2.97%	333B
NOVARTIS AG	21.52x	5.52x	13.36x	2.86%	282B
ASTRAZENECA PLC	21.56x	4.53x	12.65x	1.94%	267B
NOVO NORDISK A/S	14.17x	5.3x	10.9x	3.52%	218B
AMGEN INC.	23.78x	6.31x	11.12x	2.78%	196B
GILEAD SCIENCES, INC.	-46.02x	5.6x	31.12x	2.5%	161B
Average	16.16x	6.44x	16.46x	2.44%	397.1B
Weighted average by Cap.	23.87x	7.85x	18.16x	2%